This is wrong. eINDs are granted, based on safety, and then re-evaluated once a trial is complete and data have been analyzed.
Remember CD10 trial "impressive results" that were never released? Well they were so impressive that the FDA removed eIND for CD10 bc guess what...it doesn't work.
The exact same thing will happen with CD12.
Right now Nader is in btwn a rock and a hard place bc this is a "material event" given it's a p3 and needs to be disclosed within days or investors can sue him, the board would be held culpable, and the SEC, who is waiting to step in, will step in. So there is no way he can obfuscate the results like he did with CD10. This is going to get ugly and get ugly quickly
Market Data 
Markets 
AI
